Top Story

FDA grants orphan drug designation to Reolysin for peritoneal cancer

March 3, 2015

The FDA today granted orphan drug designation to pelareorep for the treatment of peritoneal cancer, according to a press release from the drug’s manufacturer.

Pelareorep (Reolysin, Oncolytics Biotech) has been analyzed in two sponsored clinical studies in patients with peritoneal cancer.

Sebastiano Filleti In the Journals

Most benign thyroid nodules remain benign during follow-up

March 3, 2015
A majority of asymptomatic, benign thyroid nodules had no significant change in size after 5 years of follow-up, according to study findings published in JAMA. Thyroid…

Study: No benefit from anticoagulant use in Behçet’s disease

March 3, 2015
Patients with vascular manifestations of Behçet’s disease who received treatment with anticoagulants did not benefit from the therapy given in addition to…
In the Journals

Expert discusses ASCO's policy statement on obesity–cancer link

March 3, 2015
Nearly 500,000 Americans are projected to be diagnosed with obesity-associated cancers annually by 2030, according to an ASCO press release. As previously reported in…
In the Journals

Presence of emphysema on CT scans increases lung cancer risk

March 3, 2015
Emphysema identified in low-dose CT scans increases the risk for lung cancer regardless of a patient’s smoking history, according to findings from the…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Video
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan
morganatic-roan